Description:
- Few data are available about the treatment of metastatic colorectal cancer (mCRC)
elderly patients with anti-EGFR agents in combination with chemotherapy. Up today, most
of the available data are from retrospective/post-hoc analyses, making them difficult to
translate to everyday clinical practice.
- FOLFOX plus panitumumab is a standard first-line therapy option for RAS wild-type
untreated mCRC patients. Slight adjustments in chemo-dosage are commonly applied in
routinary practice to elderly patients, but those modified schedules have never been
prospectively tested.
- In elderly patients, a reasonable upfront treatment is a fluoropyrimidine-based
monotherapy plus bevacizumab, irrespectively of the molecular status of RAS.
- BRAF mutation is a strong negative prognostic factor associated to advanced age, poor
performance status (PS), extended and aggressive disease and is associated to a lack of
benefit from anti-EGFR moAb.
- Clinical definition of elderly (over 70 years old) CRC patients that may deserve a more
or less intensive combination therapy is still debated. The cut-off of 75 years old
combined with ECOG PS assessment is a reasonable approach for clearly defining
candidates to different approaches31.
- Several geriatric screening tools have been used to identify patients with a geriatric
profile potentially predicting for overall survival and risk of toxicity. The G8
screening tool has been validated in cancer patients showing the strongest prognostic
value for overall survival; the CRASH score is able to stratify patients according an
estimated risk of treatment-related toxicities.
On the basis of these considerations, the investigators designed the present randomized phase
II trial of first-line therapy panitumumab in combination with simplified FOLFOX or with
5-fluorouracil, in previously untreated elderly patients with RAS and BRAF wild-type
unresectable mCRC.
Title
- Brief Title: Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients
- Official Title: Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients
Clinical Trial IDs
- ORG STUDY ID:
2015-003888-10
- NCT ID:
NCT02904031
Conditions
- Elderly Metastatic Colorectal Cancer Patients
Interventions
| Drug | Synonyms | Arms |
|---|
| 5-fluorouracil | | 5FU/LV plus panitumumab |
| oxaliplatin | | FOLFOX plus panitumumab |
| l-leucovorin | | 5FU/LV plus panitumumab |
| panitumumab | | 5FU/LV plus panitumumab |
Purpose
- Few data are available about the treatment of metastatic colorectal cancer (mCRC)
elderly patients with anti-EGFR agents in combination with chemotherapy. Up today, most
of the available data are from retrospective/post-hoc analyses, making them difficult to
translate to everyday clinical practice.
- FOLFOX plus panitumumab is a standard first-line therapy option for RAS wild-type
untreated mCRC patients. Slight adjustments in chemo-dosage are commonly applied in
routinary practice to elderly patients, but those modified schedules have never been
prospectively tested.
- In elderly patients, a reasonable upfront treatment is a fluoropyrimidine-based
monotherapy plus bevacizumab, irrespectively of the molecular status of RAS.
- BRAF mutation is a strong negative prognostic factor associated to advanced age, poor
performance status (PS), extended and aggressive disease and is associated to a lack of
benefit from anti-EGFR moAb.
- Clinical definition of elderly (over 70 years old) CRC patients that may deserve a more
or less intensive combination therapy is still debated. The cut-off of 75 years old
combined with ECOG PS assessment is a reasonable approach for clearly defining
candidates to different approaches31.
- Several geriatric screening tools have been used to identify patients with a geriatric
profile potentially predicting for overall survival and risk of toxicity. The G8
screening tool has been validated in cancer patients showing the strongest prognostic
value for overall survival; the CRASH score is able to stratify patients according an
estimated risk of treatment-related toxicities.
On the basis of these considerations, the investigators designed the present randomized phase
II trial of first-line therapy panitumumab in combination with simplified FOLFOX or with
5-fluorouracil, in previously untreated elderly patients with RAS and BRAF wild-type
unresectable mCRC.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| FOLFOX plus panitumumab | Experimental | Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;
Oxaliplatin 85 mg/sqm iv over 2 hours, day 1;
L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;
5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. | - 5-fluorouracil
- oxaliplatin
- l-leucovorin
- panitumumab
|
| 5FU/LV plus panitumumab | Experimental | Panitumumab 6 mg/kg iv over 60 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60 minutes;
L-Leucovorin 200 mg/sqm iv over 2 hours, day 1;
5-fluoruracil 2400 mg/sqm 48 h-continuous infusion, starting on day 1; to be repeated every 2 weeks for a maximum of 12 cycles. If no progression occurs, patients will receive maintenance panitumumab at the same dose used at the last cycle of the induction treatment. Panitumumab will be repeated biweekly until disease progression, unacceptable toxicity or patient's refusal. | - 5-fluorouracil
- l-leucovorin
- panitumumab
|
Eligibility Criteria
Inclusion criteria
- Written informed consent to study procedures and to molecular analyses.
- Histologically proven diagnosis of colorectal cancer.
- Initially unresectable metastatic colorectal cancer not previously treated with
chemotherapy for metastatic disease.
- At least one measurable lesion according to RECIST1.1 criteria.
- Availability of a tumoral sample (primary and/or metastatic sites).
- Age ≥ 70 years.
- ECOG PS 1 or 2 for patients aged 70 to 75 years; ECOG PS 0 or 1 for patients aged > 75
years.
- Life expectancy of at least 12 weeks.
- Previous adjuvant chemotherapy allowed only if with fluoropyrimidine monotherapy and
more than 6 months elapsed between the end of adjuvant and first relapse.
- RAS and BRAF status wild-type of primary colorectal cancer or related metastasis,
centrally assessed.
- Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hgb ≥ 9 g/dl.
- Total bilirubin ≤ 1.5 time the upper-normal limits (UNL) of the normal values and ASAT
(SGOT) and/or ALAT (SGPT) ≤ 2.5 x UNL (or <5 x UNL in case of liver metastases)
alkaline phosphatase ≤ 2.5 x UNL (or <5 x UNL in case of liver metastases).
- Creatinine clearance ≥ 50 mL/min or serum creatinine ≤1.5 x UNL.
- Male subjects with female partners of childbearing potential must be willing to use
adequate contraception as approved by the investigator (barrier contraceptive measure
or oral contraception).
- Geriatric assessment by means of G8 screening tool and CRASH score.
- Will and ability to comply with the protocol.
Exclusion criteria
- Previous treatment for metastatic disease.
- Radiotherapy to any site within 4 weeks before the study.
- Previous adjuvant oxaliplatin-containing chemotherapy.
- Previous treatment with EGFR inhibitors.
- Untreated brain metastases or spinal cord compression or primary brain tumors.
- History or evidence upon physical examination of CNS disease unless adequately
treated.
- Symptomatic peripheral neuropathy > 1 grade NCIC-CTG criteria.
- Creatinine clearance < 50 mL/min or serum creatinine >1.5 x UNL.
- Clinical signs of malnutrition.
- Neutrophils <1.5 x 109/L, Platelets <100 x 109/L, Hgb <9 g/dl.
- Diagnosis of interstitial pneumonitis or pulmonary fibrosis.
- Active uncontrolled infections or other clinically relevant concomitant illness
contraindicating chemotherapy administration.
- Clinically significant (i.e. active) cardiovascular disease for example
cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months), unstable
angina, New York Heart Association (NYHA) grade II or greater congestive heart failure
(CHF), serious cardiac arrhythmia requiring medication.
- Treatment with any investigational drug within 30 days prior to enrollment or 2
investigational agent half-lives (whichever is longer)
- Other co-existing malignancies or malignancies diagnosed within the last 5 years with
the exception of localized basal and squamous cell carcinoma or cervical cancer in
situ.
- Lack of physical integrity of the upper gastrointestinal tract, malabsorption
syndrome, or inability to take oral medication.
- Definite contraindications for the use of corticosteroids and antihistamines as
premedication.
- Known hypersensitivity to trial drugs or hypersensitivity to any other component of
the trial drugs.
- Any concomitant drugs contraindicated for use with the trial drugs according to the
product information of the pharmaceutical companies.
- Sexually active males unwilling to practice contraception (barrier contraceptive
measure or oral contraception) during the study and until 6 months after the last
trial treatment.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 70 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Progression Free Survival (PFS). PFS is defined as the time from randomization to the first documentation of objective disease progression or death due to any cause, whichever occurs first. |
| Time Frame: | Up to 28 months |
| Safety Issue: | |
| Description: | July 2016 - November 2018 |
Details
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Active, not recruiting |
| Lead Sponsor: | Gruppo Oncologico del Nord-Ovest |
Last Updated
May 12, 2020
